

Appl. No. 09/546,857  
Amdt. dated November 20, 2003  
Reply to Office Action of August 20, 2003

Amendments to the Specification

Please replace the paragraph beginning at page 58, line 4 with the following amended paragraph.

The present invention provides VEGF variants having at least a single one or more amino acid mutations in the KDR and/or FLT-1 receptor binding domains in the native VEGF sequence and selective binding affinity for either the KDR receptor or the FLT-1 receptor. Methods of making the VEGF variants and methods of using the VEGF variants are also provided.